2023: A year in review
Look back on UC's year of new beginnings
REPLACE WITH YOUR TEXT. Right click, and then click the pen-shaped icon.
Aliquam erat volutpat. Nunc vitae neque odio. Morbi diam lacus, lacinia et consequat nec, sagittis ac mauris. Etiam consectetur sed ipsum eget ornare. Aliquam imperdiet, massa non tincidunt faucibus, elit tortor tincidunt ante, ut semper lectus sapien vel arcu. Suspendisse in dictum metus, sit amet semper odio. Vivamus varius libero sit amet elit imperdiet finibus.
Tags
- Impact
- College of Pharmacy
- College of Medicine
- College of Allied Health Sciences
- Student Experience
- Health
- UC Online
- Alumni Association
- College of Design, Architecture, Art, and Planning
- Lindner College of Business
- Athletics
- College-Conservatory of Music
- Experience-based Learning
- College of Arts and Sciences
- College of Cooperative Education and Professional Studies
- College of Education, Criminal Justice, & Human Services
- Arts & Culture
- Faculty Staff
- Blue Ash College
- Clermont College
- Graduate College
- College of Law
- President's Office
- College of Nursing
- Next Lives Here
- College of Engineering and Applied Science
- Science & Tech
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.